Gene · 28882
IGKV2D-29: immunoglobulin kappa variable 2D-29
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. IGKV2D-29: immunoglobulin kappa variable 2D-29. Genes, record 28882. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/28882
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| A0A075B6S2 | Immunoglobulin kappa variable 2D-29 | 120 | 0 | Ensembl, HGNC |
Source UniProt
Patents6
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4650780 A2 | 2025-11-19 | 14125 | A0A075B6S2 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 14125 | A0A075B6S2 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 39848 | A0A075B6S2 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 142819 | A0A075B6S2 | Espacenet |
| WO 2020043864 A1 | 2020-03-05 | 1312 | A0A075B6S2 | Espacenet |
| WO 2019180264 A1 | 2019-09-26 | 30 | A0A075B6S2 | Espacenet |
Drugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,968
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | IGKV2D-29 papers | Newest fiscal year |
|---|---|---|---|
| ZIADK031117 | Development of Drugs Acting at Adenosine Receptors | 82 | 2025 |
| ZIADA000493 | Functional and Pharmacological Significance of Receptor Heteromers in the CNS | 25 | 2025 |
| ZIADK031126 | Computer Modeling of G Protein-Coupled Receptors | 22 | 2025 |
| ZIADK031115 | Functionalized Congeners of Bioactive Compounds | 21 | 2025 |
| ZIADK031116 | Development of P2Y Receptor Ligands | 14 | 2025 |
| ZIAAA000375 | Mechanism of oxidative/nitrosative stress and inflammation-induced tissue injury | 8 | 2025 |
| P30EY001583 | P30 Core Grant For Vision Research | 5 | 2025 |
| R01DK095491 | Indole dysbiosis and mucosal inflammation | 5 | 2025 |
| R35GM136397 | GPCR anterograde trafficking | 4 | 2025 |
| UL1TR001445 | Clinical and Translational Science Award | 4 | 2025 |
1 to 10 of 1,968Source NIH's project files
See all 1,968 nih grantsPapers3,857
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Pantoprazole as a potential repurposed drug targeting the adenosinergic system in esophageal cancer. | Med Chem Res | 2026 | 42789078 | PubTator, text mining | PubMed |
| Guanfacine and HCN channels: bridging neuroinflammation and prefrontal cortex function in autism spectrum disorder. | Front Mol Neurosci | 2026 | 42781299 | PubTator, text mining | PubMed |
| Developmental changes in Ca2+ signaling mediated by A2A adenosine and mGluR5 glutamate receptors in olfactory bulb astrocytes. | Sci Rep | 2026 | 42660969 | PubTator, text mining | PubMed |
| Reprogramming the immunosuppressive microenvironment in glioblastoma: the microglia-MDSC-Treg axis and translational therapeutic strategies. | Front Oncol | 2026 | 42639384 | PubTator, text mining | PubMed |
| Quantifying Heteromer Partitioning Reveals Inflammation-Dependent Redistribution of Microglial Adenosine A2A and Cannabinoid CB2 Receptors. | Glia | 2026 | 42482393 | PubTator, text mining | PubMed |
| Inflammation, oxidative stress and purinergic signaling in pituitary neuroendocrine tumors (PitNETs). | Purinergic Signal | 2026 | 42412139 | PubTator, text mining | PubMed |
| Circulating ATP from hepatic ischemia-reperfusion drives remote cardiac injury via macrophage inflammasome activation. | Pharmacol Res | 2026 | 42309495 | PubTator, text mining | PubMed |
| Computational evaluation of leflunomide and ticagrelor combination targeting the A2A receptor for the management of rheumatoid arthritis. | Pak J Pharm Sci | 2026 | 42262197 | PubTator, text mining | PubMed |
| Adenosine Signaling in Primary and Metastatic Brain Tumors: Immune Suppression, Tumor Progression, and Therapeutic Opportunities. | Mol Neurobiol | 2026 | 42168394 | PubTator, text mining | PubMed |
| Discovery of Potent 1,3-Cyclobutane-Containing Dual A2A/A2B Receptor Antagonists with Low Projected Human Dose for the Treatment of Cancer. | ACS Med Chem Lett | 2026 | 42157841 | PubTator, text mining | PubMed |
1 to 10 of 3,857
See all 3,857 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/28882
GET https://conductscience.org/api/genes/v1/28882/grants?page=2